Clinical Trial Update: Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1 [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating pembrolizumab plus anlotinib as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma with CPS≥1.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Shi Yuankai | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN